MBIO stock sits near its 52-week low as Nasdaq deadline nears

Published on 10/07/2026 at 03:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

MBIO stock traded at USD 0.460 on October 6, 2026, 0.44 percent above its 52-week low. Mustang Bio reported a USD 1.072 million Q2 loss, while its Nasdaq compliance deadline is October 12.

MBIO, US62818Q3020, Illustration mit AI erstellt.

Mustang Bio (ISIN US62818Q3020) stock was trading at USD 0.460 on Nasdaq on October 6, 2026, 0.44 percent above its 52-week low of USD 0.458. The clinical-stage biotechnology company is approaching a key listing deadline after reporting another quarterly loss.

Q2 loss reaches USD 1.072 million

For the quarter ended June 30, 2026, Mustang Bio reported a net loss of USD 1.072 million and operating expenses of USD 1.17 million, according to StockTitan. Operating expenses increased 32 percent from the prior-year period, making cost control a central issue for a company still advancing its cell therapy pipeline.

The first six months of 2026 produced a net loss of USD 2.0 million. Mustang Bio's adjusted? No. The reported figures are GAAP results, and the comparison is between the same reported period and the prior year.

Cash provides limited operating room

Cash and cash equivalents stood at USD 15.2 million on June 30, 2026, while total assets were USD 15.6 million and stockholders' equity was USD 7.5 million, StockTitan reported. Operating cash flow was negative USD 967,000 in Q2 2026, which places financing and clinical execution alongside the listing requirement in the near-term investor view.

Mustang Bio develops CAR T and oncolytic virus programs aimed at difficult-to-treat cancers. Its investor-relations page identifies Q2 2026, ended June 30, 2026, as the latest financial reporting period and describes partnerships with medical institutions for CAR T development, according to Mustang Bio.

Nasdaq deadline is October 12

Nasdaq notified Mustang Bio in April 2026 that its share price had fallen below the USD 1.00 minimum bid requirement. The company has until October 12, 2026, to regain compliance or face the risk of delisting, according to StockTitan.

MBIO remains near its yearly low

On October 6, 2026, MBIO's 52-week range was USD 0.458 to USD 1.850, and its market capitalization was USD 3.5 million, based on the Nasdaq quote page published by Investing.com. The USD 0.460 price therefore sat near the bottom of that range, while the October 12 compliance date gives the stock a defined regulatory checkpoint.